AbbVie has announced four new research collaborations with leading healthcare innovators to advance early-stage research in key therapeutic areas.
The company will work together with Pure MHC on a research and licence agreement to discover and validate peptide targets for use with T-cell receptor therapeutics, for the treatment of several types of cancer.
“AbbVie has announced four new research collaborations with Pure MHC, Dong-A-ST, Zebra Biologics and Genomics Medicine Ireland.“
Also in the field of oncology, the firm will collaborate with South Korea's Dong-A-ST to study MerTK inhibitors in preclinical development for use in conjunction with immuno-oncology therapies.
Meanwhile, an alliance with Zebra Biologics has been agreed, with the aim of discovering agonist antibody therapeutics for inflammatory diseases. This will leverage Zebra's novel and patented function-based antibody discovery platform to generate antibodies.
Finally, a partnership with Genomics Medicine Ireland will see AbbVie conduct population genomics research in Ireland, sequencing the genomes of 45,000 volunteers to assess several types of immune-mediated diseases, neurological disorders and cancer.
Dr Michael Severino, executive vice-president for research and development and chief scientific officer at AbbVie, said: "Combining the strengths of AbbVie's discovery and development expertise and novel research from external partners will accelerate the pace of innovation into new medicines for the next-generation of medical treatment."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical